SCHEMBL4833496

SCHEMBL4833496

NC1=c2ccsc2=NCN1c1ccc(NC(=O)C=Cc2ccccc2Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.50
▸ RAB9A P51151 7/20 0.50
▸ NPC1 O15118 5/20 0.50
▸ MAOB P27338 2/20 0.50
▸ MAOA P21397 1/20 0.50
▸ KMT2A Q03164 9/20 0.49
▸ MEN1 O00255 7/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ TP53 P04637 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ LMNA P02545 3/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833486 1.00 MAPT (0.50) MAPTRAB9ANPC1MAOBMAOA
SCHEMBL4833283 0.87 MAPT (0.52) MAPTRAB9ANPC1MAOBMAOA
SCHEMBL4833308 0.87 MAPT (0.52) MAPTRAB9ANPC1MAOBMAOA
SCHEMBL4834149 0.84 MEN1 (0.51) MAPTRAB9ANPC1MAOBMAOA
SCHEMBL4835290 0.77 RAB9A (0.49) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL4834603 0.74 BAZ1A (0.41) MAPTNPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4828766 0.73 RAB9A (0.47) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL4833891 0.72 MAPT (0.54) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL4831085 0.72 SCN3A (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL4833753 0.72 SCN3A (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885RAB9A 3248/4885NPC1 4117/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885RAB9A 4166/4885NPC1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback